Endothelial Dysfunction in Heart Failure: Possibilities of Therapy with Angiotensin Converting Enzyme Inhibitors

Kardiologiya

Volumn 41, Issue 5, 2001, Pages 100-104

  Belenkov, Yu N ^a   Mareev, V Yu ^a   Ageev, F T ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Angiotensin convening enzyme inhibitors; Heart failure, chronic, treatment, pathogenesis; Vasodilators, peripheral, neurohumoral

Indexed keywords

EID: 0347786302     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. LeJmtel T.H., Mascin C.S., Lucido D. et al. Failure to augment maximal limb blood flow in responce to one leg versus two-leg exercise in patients with severe heart failure. Circulation 1986;7444:245-251.
2. Drexler H.,Banhardt U., Meinertz T. et al.Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebocontrolled trial. Circulation 1989;79:491-502.
3. Furchgott R.F., Zawadzki J.V. The obligatory role of the endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
4. Dzau V.J. Tissue renin-anaiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-942.
5. Fabris B., Chen B., Pupic V. et al. Inhibition of angiotensinconverting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol 1990;15:Suppl 2:S6-S13.
6. Ferrari R., Bachetti T., Guardigli G. et al. Bradykinin and coronary artery disease. Eur Heart J 2000;2:Suppl H:H14-H19.
7. Vanhoutte P.M., Boulanger C.M., Illiano S.C. et al. Endothelium-dependent effects of converting enzyme inhibitors. J Cardiovasc Pharmacol 1993;22:Suppl 5:S10-S16.
8. Horing C., Kohler C., Drexler II. Role of bradykinin in mediating vascular effects of ACE inhibitors in humans. Circulation 1997; 95:1115-1118.
9. Fabre J.-E., Rivard A., Magner M. et al. Tissue inhibition of angiothensin - converting enzyme activity simulates angiogenesis in vivo. Circulation 1999;99:3043-3049.
10. Mancini G.B.J., Henry G.C., Macaya C. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996;94:258-265.
11. Horing B., Arakawa N., Haussmann D. et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98:2842-2848.
12. Riegger G.A.J. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J 1991;12:705-711.
13. Northridge D.B., Rose E., Raftery E.D. et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur Heart J 1993;14:403-409.
14. Beynon J.H., Pathy M.S.J. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure. Curr Med Res Opin 1997;13:583-592.
15. Anderson T.J., Elstein E., IIaber H. et al. Comparative study of ACE-Inhibition, angiotensin II antagonism, and calcium channel blockade on flow mediated vasodilatation in patients with coronary disease (BANFF Study). J Am Coll Cardiol 2000;35:60-66.
16. Lees R.S., Pitt B., Chan R.C. et al. Baseline clinical and angiographic data in the Quinapril Ischaemic Event Trial (QUIET). Am J Cardiol 1996;78:1011-1016.
17. Oosterga M., Voors A.A., Buikema H. et al. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. Cardiovasc Drugs Ther 2000;14:55-60.
18. Canter D., Frank G.J., Knapp L.E. et al. Quinapril and hydrochlorthiazide combination for control of hypertension: assessment by factoral design. J Human Hypert 1994;8:155-162.
19. Antony I., Lerebours G. et al. Angiotension converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilatations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-3122.
20. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in hiah-risk patients. N Engl J Med 2000:342:145-153.
21. Prasad A., Husain S. et al. Coronary endothelial dysfunction in humans improves with angiotension convening enzyme inhibition. Circulation 1996;94:Suppl I:Abstract1:61.